Editing Celecoxib (section)

===Drug interactions===
Celecoxib undergoes metabolism primarily by the enzymes [[CYP2C9]] and [[CYP3A4]], but it also interacts with [[CYP2D6]], inhibiting its activity without being metabolized by it.<ref name="Shkundin_2025">{{cite journal | vauthors = Shkundin A, Wheeler HE, Sinacore J, Halaris A | title = BDNF/BDNF-AS Gene Polymorphisms Modulate Treatment Response and Remission in Bipolar Disorder: A Randomized Clinical Trial | journal = Journal of Personalized Medicine | volume = 15 | issue = 2 | pages = 62 | year = 2025 | doi = 10.3390/jpm15020062 | doi-access = free| pmid = 39997339 | pmc = 11856652 }}</ref> The CYP2C9 gene exhibits considerable genetic variability, with common polymorphisms, such as [[CYP2C9 | rs1799853]] and [[CYP2C9 | rs1057910]], linked to reduced enzyme activity and altered pharmacokinetics of celecoxib.<ref name="Shkundin_2025"/> Additionally, the influence of CYP2D6 on celecoxib metabolism is inconsistent, with its effect varying depending on the individual’s CYP2C9 genetic profile.<ref name="Shkundin_2025"/>

Caution must be exercised with concomitant use of 2C9 inhibitors, such as [[fluconazole]], which can greatly elevate celecoxib serum levels.<ref name="Celebrex FDA label"/> If used concomitantly with lithium, celecoxib increases lithium plasma levels.<ref name="Celebrex FDA label"/> If used concomitantly with warfarin, celecoxib may result in an increased risk of bleeding complications.<ref name="Celebrex FDA label"/> The risk of bleeding and gastric ulcers also increases further when [[selective serotonin reuptake inhibitor]]s (SSRI) are used in combination with celecoxib.<ref>{{cite journal | vauthors = Turner MS, May DB, Arthur RR, Xiong GL | title = Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks | journal = Journal of Internal Medicine | volume = 261 | issue = 3 | pages = 205–213 | date = March 2007 | pmid = 17305643 | doi = 10.1111/j.1365-2796.2006.01720.x | s2cid = 41772614 | doi-access = free }}</ref> The drug may increase the risk of kidney failure with [[angiotensin]]-converting enzyme-inhibitors, such as [[lisinopril]], and [[diuretic]]s, such as [[hydrochlorothiazide]].<ref name="Celebrex FDA label"/>